金陵药业 (000919)

JINLING PHARMACEUTICAL CO.,LTD

ASZ

Tags

Venture Capital ConceptChemical PharmaceuticalsMedical Aesthetics ConceptSmall Cap State-Owned EnterprisesSmart HealthcarePrivate HospitalsSZSE Medicine Equal Weight IndexPharmaceutical IndexSina 100 IndexShenzhen A-Share Pharmaceutical IndexCSI All-share Pharmaceutical Sector IndexStocks Below Placement PriceLocal State-owned Assets ReformYangtze River Delta Economic ZoneHuijin ConceptShareholding Increase CommitmentStocks Below Book ValueVenture Capital

K-Line Chart

No K-line data available

Company NameJinling Pharmaceutical Co., Ltd.
Listing Date1999-11-18
Issue Price8.4RMB
Registered Capital62192.452810k RMB
Legal RepresentativeChen Sheng
Registered AddressNo. 58 Xingang Avenue, Nanjing Economic and Technological Development Zone, Jiangsu Province
IndustryChemical Pharmaceuticals
Main BusinessPharmaceutical manufacturing and medical, health, and wellness services.
Company ProfileJinling Pharmaceutical Co., Ltd. (000919) is a large modern listed company established in September 1998 under modern enterprise system requirements. It was jointly initiated by five entities, including Nanjing Jinling Pharmaceutical (Group) Co., Ltd., contributing high-quality assets. The company integrates science, industry, and trade, combining production, education, and research. Adhering to the business philosophy of 'Integrity as the foundation, focusing on modern Chinese medicine,' the company has formed a strategic pattern primarily focused on Chinese patent medicines, with the development goal of integrating Chinese and Western medicines. It currently boasts total assets of 1.6 billion yuan, net assets of 1.2 billion yuan, and over 2,000 employees. The company has been honored with titles such as National Key Enterprise among the Top 520, National Customer Satisfaction Enterprise, National High-Tech Enterprise, Enterprise with Outstanding Contribution to Chinese Enterprise Management, Second Prize for Modernization Innovation Achievements in Chinese Enterprise Management, Key Intellectual Property Protection Unit in Jiangsu Province, and 'Civilized Unit' and 'Excellent Enterprise' in Jiangsu Province and Nanjing City. Since successfully issuing and listing 80 million A-shares on the Shenzhen Stock Exchange in August 1999, the company has maintained an annual return on net assets above 10%, with an asset-liability ratio around 20%. It possesses strong financing capabilities and capital expansion potential in both the money and capital markets.

Stock Details

1. Key Indicators

  • Total Shares(W): 62192.45
  • Circulating A-Shares(W): 62176.67
  • Earnings Per Share(RMB): 0.1101
  • Net Assets Per Share(RMB): 6.0803
  • Operating Revenue(W RMB): 238014.30
  • Total Profit(W RMB): 8971.11
  • Net Profit Attributable to Parent(W RMB): 6845.83
  • Net Profit Growth Rate(%): -4.08
  • Weighted Return on Equity(%): 1.8000
  • Operating Cash Flow Per Share(RMB): 0.1430
  • Undistributed Profit Per Share(RMB): 2.6726
  • Capital Reserve Per Share(RMB): 1.7448

2. Main Business

The main business covers:

  • Pharmaceutical Manufacturing
  • Medical Device Manufacturing
  • Medical, Health and Elderly Care Services

3. Company Basic Information

  • Company Name: Jinling Pharmaceutical Company Limited
  • Listing Date: 1999-11-18
  • Industry: Pharmaceutical Manufacturing
  • Address: Jinling Pharmaceutical Building, No. 238 Zhongyang Road, Nanjing City, Jiangsu Province
  • Website: www.jlyy1999.com
  • Company Profile: The company was established on September 8, 1998, as a joint-stock company initiated by Nanjing Jinling Pharmaceutical (Group) Co., Ltd., the Management Bureau of Fuzhou General Hospital of Nanjing Military Region, the Management Bureau of Suzhou Enterprises of Nanjing Military Region Logistics Department, the First Branch of the Management Bureau of Nanjing Enterprises of Nanjing Military Region Logistics Department, and the Management Bureau of Xuzhou Enterprises of Nanjing Military Region Logistics Department. The initiator, Nanjing Jinling Pharmaceutical (Group) Co., Ltd., contributed its affiliated Jinling Pharmaceutical Factory, and other initiators respectively contributed the evaluated and confirmed operating net assets of Fuzhou Meifeng Pharmaceutical Factory, Zhejiang Tianfeng Pharmaceutical Factory, Nanjing Jinwei Natural Beverage Company, and Hefei Limin Pharmaceutical Factory, totaling 260.0255 million yuan, which were converted into 200 million shares at a ratio of 76.92%. After issuing 80 million public shares (including 8 million shares allocated to investment funds) on August 27, 1999, the company's total share capital reached 280 million shares. Its 80 million public shares were listed and traded on the Shenzhen Stock Exchange on November 18, 1999.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Nanjing Xingong Investment Group Co., Ltd. General Legal Person 22794.38 38.61
2 Fuzhou Investment Management Co., Ltd. General Legal Person 2300.37 3.90
3 Hefei Industrial Investment Holding Co., Ltd. General Legal Person 971.13 1.65
4 Zhejiang International Trade Group Co., Ltd. General Legal Person 622.49 1.05

5. Concept Sectors

  • Venture Capital Concept
  • Elderly Care Concept
  • Private Hospital
  • Smart Healthcare
  • Medical Aesthetics Concept
  • Innovative Drugs
  • Recent Highs
  • Strong Yesterday
  • Small-Cap State-Owned Enterprise

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information